Qiagen N.V. (QGEN) AI Stock Analysis

Qiagen N.V. is a global provider of end-to-end solutions that unlock molecular insights from biological samples. Founded in 1986 and based in Venlo, the Netherlands, the company specializes in sample to insight technologies covering nucleic acid purification, sample processing automation, and molecular analysis tools. Its offerings include nucleic acid stabilization kits, purification systems using silica membranes and magnetic beads, and automated instruments for genotyping, viral detection, and gene expression analysis. Qiagen serves molecular diagnostics, academic research, pharmaceutical development, and applied testing customers. It also supplies specialized assays, custom NGS gene panels, library preparation kits, and bioinformatics tools, working alongside partners including Sysmex Corporation, OncXerna Therapeutics, and Mirati.

Qiagen grew revenue by 5.7% in FY2025 to $2.09B, recovering from $1.98B in FY2024 and $1.97B in FY2023, following declines of 4.9% in FY2022 and 8.2% in FY2023. Gross margin expanded to 61.8% in FY2025 from 48.9% in FY2024, while operating margin rebounded to 24.9% from 4.9%. Net income reached $424.9M in FY2025 compared to $83.6M in FY2024. Over the 5-year period from FY2020 to FY2025, revenue posted a CAGR of 2.2%. In the latest quarter ended June 30, 2026, revenue increased 0.3% year-over-year, while quarterly earnings expanded 7.9% year-over-year. TTM operating margin stood at 26.3% on $2.10B in revenue.

As of June 30, 2026, Qiagen held $793.5M in cash and short-term investments against total debt of $1.64B, leaving net debt at $850.1M. The company maintains a current ratio of 2.85 and a debt-to-equity ratio of 0.49 against $3.36B in shareholders' equity. In FY2025, operating cash flow was $654.3M and free cash flow reached $453.3M. Cash allocation in FY2025 included $201.0M in capital expenditures, $307.4M in share buybacks, and $54.2M in dividends paid. Over five years, the share count decreased 10.3%.

Qiagen trades at a trailing P/E of 23.4x, slightly below the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 13.5x is lower than the peer median of 17.3x, and its PEG ratio is 1.17. Enterprise value to EBITDA is 14.0x, above the peer median of 12.0x, while price-to-sales of 4.5x compares to 4.1x for peers. Over the past year, the stock returned 1.9%, trailing the S&P 500 return of 16.8%. Over 5 years, the stock returned -1.7% compared to an 83.0% gain for the S&P 500.

Qiagen pays an annual dividend with a forward rate of $0.35 per share, representing a dividend yield of 0.76%. The payout ratio stands at 114.1%, and the dividend has been paid for 3 consecutive years. The company's last ex-dividend date occurred on July 7, 2026.

Wall Street coverage consists of 4 Strong Buy, 5 Buy, and 7 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target is $48.13, representing 4.3% upside from the last close of $46.13. For the fiscal year ending December 31, 2026, analysts estimate EPS of $2.43 on revenue of $2.14B. For the following fiscal year, 13 analysts project EPS of $2.61 and revenue of $2.24B, indicating 5.1% revenue growth. Qiagen beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Qiagen N.V. (QGEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: QGEN income statement, QGEN balance sheet, QGEN key metrics, QGEN analyst forecast, QGEN chart. See the QGEN stock overview for the latest quote and news.